With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1165923-89-6,tert-Butyl 6-hydroxy-5-methyl-3,4-dihydroisoquinoline-2(1H)-carboxylate,as a common compound, the synthetic route is as follows.
1165923-89-6, To a solution of 1 ,1-dimethylethyl 6-hydroxy-5-methyl-3,4-dihydro-2(1 H)- isoquinolinecarboxylate (Preparation 168) (3.16g, 12 mmol) in DCM (50ml) at room temperature under nitrogen was added pyridine (1.94ml, 24 mmol) and the resulting solution was cooled to -300C before trifluoromethanesulfonic anhydride (2.23ml, 13.20 mmol) was added dropwise. The resulting mixture was stirred for 40min at this temperature, warmed to room temperature and concentrated. The residue was diluted with ethyl acetate and washed sequentially with a hydrochloric acid (1 N), saturated sodium hydrogen carbonate and brine. The solution was dried (MgSO4) and concentrated in vacuo to give 1 ,1-dimethylethyl 5-methyl-6- {[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2(1 H)-isoquinolinecarboxylate (4.85g, 102%) as a red oil which was used in the next step (Preparation 22) without further purification. LCMS (Method HpH): Retention time 1.46min, [M-H]” = 3941 H NMR (CDCI3): deltaH 7.10(1 H, d), 7.02(1 H, d), 4.58(2H, s), 3.68(2H, t), 2.76(2H, t), 2.25(3H, s), 1.49(9H, s).
1165923-89-6 tert-Butyl 6-hydroxy-5-methyl-3,4-dihydroisoquinoline-2(1H)-carboxylate 54756910, aisoquinoline compound, is more and more widely used in various fields.
Reference£º
Patent; GLAXO GROUP LIMITED; BAILEY, James, Matthew; BIT, Rino, Antonio; DEMONT, Emmanuel, Hubert; HARRISON, Lee, Andrew; JONES, Katherine, Louise; SMETHURST, Christian, Alan, Paul; WITHERINGTON, Jason; WO2010/146105; (2010); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem